CEP-18770

DRUG3 trials

Sponsors

Ethical Oncology Science, Cephalon, Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Lymphoma, Non-HodgkinMultiple MyelomaSolid Tumors

Phase 1

Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

CompletedNCT00572637

Ethical Oncology ScienceLymphoma, Non-Hodgkin, Solid Tumors

Start: 2007-11-30End: 2010-03-31Target: 55Updated: 2010-05-20

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

TerminatedNCT01023880

CephalonMultiple Myeloma

Start: 2010-01-31End: 2013-01-31Updated: 2016-04-11

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

CompletedNCT01348919

Teva Branded Pharmaceutical Products R&D, Inc.Multiple Myeloma

Start: 2011-08-03End: 2013-03-14Updated: 2023-06-28